{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=repaglinide+0.5+mg+tablet", "query": { "intervention": "repaglinide 0.5 mg tablet" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T01:38:34.226Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05469113", "title": "A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Repaglinide", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2019-01-29", "completion_date": "2019-03-05", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-09-25T01:38:34.226Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05469113" }, { "nct_id": "NCT07372625", "title": "A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "TP53 Y220C Mutation", "Advanced Solid Tumors" ], "interventions": [ { "name": "metformin hydrochloride 500 mg tablet", "type": "DRUG" }, { "name": "rosuvastatin 10 mg tablet", "type": "DRUG" }, { "name": "repaglinide 0.5 mg tablet", "type": "DRUG" }, { "name": "midazolam hydrochloride syrup", "type": "DRUG" }, { "name": "rezatapopt", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PMV Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2026-02-04", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-25T01:38:34.226Z", "location_count": 5, "location_summary": "Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07372625" }, { "nct_id": "NCT06165146", "title": "A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Repaglinide", "type": "DRUG" }, { "name": "Pirtobrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2020-11-10", "completion_date": "2020-12-30", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-09-25T01:38:34.226Z", "location_count": 1, "location_summary": "Daytona Beach, Florida", "locations": [ { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06165146" }, { "nct_id": "NCT03723395", "title": "A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-drug Interaction" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "itraconazole", "type": "DRUG" }, { "name": "rifampin", "type": "DRUG" }, { "name": "gemfibrozil", "type": "DRUG" }, { "name": "repaglinide", "type": "DRUG" }, { "name": "tolbutamide", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" }, { "name": "digoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 116, "start_date": "2018-09-17", "completion_date": "2018-12-28", "has_results": false, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-09-25T01:38:34.226Z", "location_count": 2, "location_summary": "Daytona Beach, Florida • Dallas, Texas", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03723395" }, { "nct_id": "NCT04530981", "title": "A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "GIST - Gastrointestinal Stromal Tumor" ], "interventions": [ { "name": "Ripretinib", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-09-22", "completion_date": "2024-07-29", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-25T01:38:34.226Z", "location_count": 3, "location_summary": "Jacksonville, Florida • Miami, Florida • Portland, Oregon", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04530981" }, { "nct_id": "NCT06290050", "title": "A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Midazolam", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "TAK-279", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2024-03-29", "completion_date": "2024-05-16", "has_results": false, "last_update_posted_date": "2024-05-23", "last_synced_at": "2026-09-25T01:38:34.226Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06290050" }, { "nct_id": "NCT06948747", "title": "A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD5004", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Erythromycin", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 49, "start_date": "2025-05-06", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-09-25T01:38:34.226Z", "location_count": 1, "location_summary": "Brooklyn, Maryland", "locations": [ { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948747" } ] }